That's an anecdote, not data. The last article I read about this calculated that around 20% of new drug approvals came directly from government/academic research - and that's usually repurposed older drugs (which is actually a good place to focus, since it's cheaper and big pharma isn't really interested in resurrecting off-patent molecules).